Clinical trial
Docetaxel With or Without Imatinib Mesylate in Treating Patients With…
NCT00080678 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00080678 |
|---|---|
| Title | Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases |
| Official title | Randomized Double-Blind Phase II Trial of Docetaxel and Imatinib Versus Docetaxel and Placebo in Metastatic Androgen-Independent Prostate Cancer (AIPC) With Bone Metastases |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Cancer, Prostate Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Imatinib Mesylate |
| Enrollment | 116 |
| Start date | May 1, 2003 |
| Primary completion | Aug 1, 2005 |
| Completion | Mar 1, 2008 |
| First posted | Apr 8, 2004 |
| Last update posted | Oct 12, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: